Prostate cancer survivors Mark V. Williamson and Jim East will celebrate with other men who beat the disease, Nov. 16 at the ...
GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...
India Today on MSN
Why some men don't respond to prostate cancer therapy
The baffling question: why does prostate cancer relapse quickly in some patients while stabilising in others? Recent ...
A new study underway at St. David’s Surgical Hospital could help men recover faster and live a better quality of life after ...
Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global ...
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented posters at the 2025 EORTC-NCI ...
An international collaboration of researchers, including Imperial College London and UCLA, has developed a collagen-binding ...
The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.
The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...
GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...
Former President Biden said the country is in the midst of “dark days” under President Trump. “Friends, I can’t sugarcoat any ...
Biden called the current political climate “dark days” but urged Americans to "keep the faith" and “get back up.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback